Emanuela Taioli1, Raja Flores2. 1. Department of Population Health Science and Policy and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: Emanuela.taioli@mountsinai.org. 2. Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.
Abstract
INTRODUCTION: Black patients with lung cancer receive an operation less often and have worse survival than white patients. Over the past several decades limited resection has become an acceptable alternative to lobectomy in selected cases, and mediastinal lymph node staging is recommended. The Surveillance, Epidemiology, and End Results database was explored to assess whether the type of surgical approach is similar in black and white patients with lung cancer. METHODS: All cases of pathologically proven lung cancers within the site code International Classification of Diseases for Oncology, Third Edition, C340 to C349 (67,191 whites and 13,387 blacks), age 64 years or younger, diagnosed between 2007 and 2012 were identified. The odds of treatment (operation or radiation) in blacks versus whites were calculated using multivariable logistic regression, with race as the dependent variable, overall and by disease stage. RESULTS: Surgical treatment was significantly less likely to be administered to black patients than to white patients overall (ORadjusted [ORadj] = 0.69, 95% confidence interval [CI]: 0.65-0.74) and according to stage. Opposite results were observed when radiation was analyzed (ORadj = 1.1, 95% CI: 1.04-1.12). Stratification by age groups (≤50 years versus >50 years) or insurance status did not influence the results. Among those who underwent a surgical procedure, black patients were less likely to have their lymph nodes resected overall (ORadj = 0.79, 95% CI: 0.7-0.89) and according to stage. CONCLUSIONS: Racial disparities in appropriate lung cancer treatment are still observed independently from insurance status.
INTRODUCTION: Black patients with lung cancer receive an operation less often and have worse survival than white patients. Over the past several decades limited resection has become an acceptable alternative to lobectomy in selected cases, and mediastinal lymph node staging is recommended. The Surveillance, Epidemiology, and End Results database was explored to assess whether the type of surgical approach is similar in black and white patients with lung cancer. METHODS: All cases of pathologically proven lung cancers within the site code International Classification of Diseases for Oncology, Third Edition, C340 to C349 (67,191 whites and 13,387 blacks), age 64 years or younger, diagnosed between 2007 and 2012 were identified. The odds of treatment (operation or radiation) in blacks versus whites were calculated using multivariable logistic regression, with race as the dependent variable, overall and by disease stage. RESULTS: Surgical treatment was significantly less likely to be administered to black patients than to white patients overall (ORadjusted [ORadj] = 0.69, 95% confidence interval [CI]: 0.65-0.74) and according to stage. Opposite results were observed when radiation was analyzed (ORadj = 1.1, 95% CI: 1.04-1.12). Stratification by age groups (≤50 years versus >50 years) or insurance status did not influence the results. Among those who underwent a surgical procedure, black patients were less likely to have their lymph nodes resected overall (ORadj = 0.79, 95% CI: 0.7-0.89) and according to stage. CONCLUSIONS: Racial disparities in appropriate lung cancer treatment are still observed independently from insurance status.
Authors: Carol M Lewis; Gaurav S Ajmani; Alexandra Kyrillos; Paul Chamberlain; Chi-Hsiung Wang; Cheryl C Nocon; Monica Peek; Mihir K Bhayani Journal: Head Neck Date: 2018-06-26 Impact factor: 3.147
Authors: Samuel Cykert; Eugenia Eng; Paul Walker; Matthew A Manning; Linda B Robertson; Rohan Arya; Nora S Jones; Dwight E Heron Journal: Cancer Med Date: 2019-02-04 Impact factor: 4.452
Authors: Julie A Lynch; Brygida Berse; Merry Rabb; Paul Mosquin; Rob Chew; Suzanne L West; Nicole Coomer; Daniel Becker; John Kautter Journal: BMC Cancer Date: 2018-03-20 Impact factor: 4.430
Authors: John M Varlotto; Kerri McKie; Rickie P Voland; John C Flickinger; Malcolm M DeCamp; Debra Maddox; Paul Stephen Rava; Thomas J Fitzgerald; William Walsh; Paulo Oliveira; Negar Rassaei; Jennifer Baima; Karl Uy Journal: Front Oncol Date: 2018-05-14 Impact factor: 6.244